Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenretinide SCHEMBL4996036 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL839699 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL13402304 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL9838209 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL19121 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL15703189 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL10629371 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL11703 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL4874840 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL17593790 | 0.99 | RBP4 (0.98) | RBP4ALDH1A1MAPTHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25336 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4727979-A2 | COMPOSITIONS AND METHODS FOR TARGETING EXTRACELLULAR DNA | Caris Science, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | claimed |
| US-20250382580-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | UNIV COLORADO REGENTS (US) | 2025-12-18 | — | — | US | claimed |
| EP-4654969-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0711276-A1 | PROCESS FOR THE PREPARATION OF N-(4-HYDROXYPHENYL)-RETINAMIDE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-05-15 | — | — | EP | claimed |
| US-5464870-A | Antitumor | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-11-07 | — | — | US | claimed |
| US-5399757-A | Process for the preparation of N-(4-hydroxyphenyl)-retinamide | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-03-21 | — | — | US | claimed |
| WO-1995003274-A1 | PROCESS FOR THE PREPARATION OF N-(4-HYDROXYPHENYL)-RETINAMIDE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-02-02 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-5010107-A | Dietary supplement of calcium glucarate to inhibit beta-glucoronidase and N-hydroxyphenyl retinamide to elevate cyclic AMP | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1991-04-23 | — | — | US | claimed |
| US-5008291-A | Dietary supplement containing calcium glucarate and n-(4-hydroxyphenyl)retinamide; treating mammary cancer | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1991-04-16 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4665098-A | BREAST AND BLADDER CANCER, ACNE, PSORIASIS | MCNEILAB, INC. (US) | 1987-05-12 | — | — | US | claimed |